10-Q: Protagonist Therapeutics Reports Positive Q1 2025 Results Driven by Collaboration Revenue

Protagonist Therapeutics' Q1 2025 results show a net loss of $11.655 million, but are highlighted by $28.321 million in license and collaboration revenue, primarily from the Takeda agreement.

Summary

• Protagonist Therapeutics reported a net loss of $11.655 million for the first quarter of 2025, compared to a net income of $207.340 million for the same period in 2024.
• License and collaboration revenue totaled $28.321 million, primarily driven by the Takeda collaboration agreement.
• Research and development expenses increased to $35.893 million, up from $33.734 million in the prior year.
• General and administrative expenses decreased to $11.738 million from $14.910 million.
• Interest income increased to $7.573 million due to higher invested balances.
• The company's cash, cash equivalents, and marketable securities totaled $697.9 million as of March 31, 2025.
• Protagonist expects existing cash, cash equivalents, and marketable securities will be sufficient to fund operations for at least the next twelve months.
• The company anticipates submitting an NDA for rusfertide in the fourth quarter of 2025.
• JNJ's Phase 2b Anthem-UC trial of icotrokinra in adults with moderately-to-severely active UC met its primary endpoint of clinical response in all icotrokinra dose groups evaluated.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reported a net loss, it has a strong cash position and positive clinical trial results, suggesting potential for future growth. The potential need for additional funding and macroeconomic uncertainties temper the outlook.

Positives

• The company has $697.9 million in cash, cash equivalents, and marketable securities, providing a strong financial position.
• The Phase 3 VERIFY trial of rusfertide met its primary endpoint, potentially leading to an NDA filing in the fourth quarter of 2025.
• JNJ's Phase 2b Anthem-UC trial of icotrokinra in adults with moderately-to-severely active UC met its primary endpoint of clinical response in all icotrokinra dose groups evaluated.
• The company expects to nominate a development candidate for an oral hepcidin mimetic or ferroportin inhibitor in the fourth quarter of 2025.
• The company expects to nominate a development candidate for an oral peptide-based anti-obesity program by the end of the second quarter of 2025.

Negatives

• The company reported a net loss of $11.655 million for Q1 2025, a significant decrease compared to the $207.340 million net income in Q1 2024.
• License and collaboration revenue decreased from $254.953 million in Q1 2024 to $28.321 million in Q1 2025.
• The company has an accumulated deficit of $352.2 million.

Risks

• The company's ultimate success depends on the outcome of its research and development and collaboration activities.
• The company may need to raise additional capital to continue to execute its long-range business plan.
• Unstable market and macroeconomic conditions, including elevated and sustained inflation and changes in tariffs or trade policy, may have serious adverse consequences on our business, financial condition and stock price.
• Disruptions at the FDA and other government agencies could negatively affect the review of our regulatory submissions, which could negatively impact our business.

Future Outlook

Protagonist Therapeutics anticipates submitting an NDA for rusfertide in the fourth quarter of 2025 and expects existing cash, cash equivalents, and marketable securities will be sufficient to fund operations for at least the next twelve months.

Industry Context

Protagonist Therapeutics operates in the competitive biopharmaceutical industry, focusing on peptide therapeutics. The company's clinical programs target inflammatory and immunomodulatory diseases, as well as hematology and blood disorders. The success of rusfertide and icotrokinra could position Protagonist as a key player in these therapeutic areas. Competitors include companies developing treatments for polycythemia vera, ulcerative colitis, and psoriasis.

Comparison to Industry Standards

• Protagonist's collaboration with Takeda for rusfertide is similar to other partnerships in the biotech industry, such as the collaboration between Vertex Pharmaceuticals and CRISPR Therapeutics for gene-editing therapies.
• The $300 million upfront payment from Takeda is comparable to other significant licensing deals in the pharmaceutical sector.
• The tiered royalty rates of 10% to 17% on ex-U.S. net sales of rusfertide are within the typical range for pharmaceutical royalties.
• The company's focus on oral peptide therapeutics aligns with the industry trend toward developing more convenient and patient-friendly drug delivery methods.
• The Phase 3 VERIFY trial results for rusfertide are being compared to existing treatments for polycythemia vera, such as Jakafi (ruxolitinib) from Incyte.

Stakeholder Impact

• Shareholders: The net loss may negatively impact shareholder value in the short term, but positive clinical trial results and a strong cash position offer potential for future gains.
• Employees: Continued investment in research and development suggests job security and potential for growth within the company.
• Customers (Patients): Successful development and approval of rusfertide and icotrokinra could provide new treatment options for polycythemia vera, ulcerative colitis, and psoriasis.
• Suppliers: Ongoing clinical trials and research activities will continue to generate demand for clinical supplies and services.
• Creditors: The company's strong cash position reduces the risk of default on debt obligations.

Next Steps

• Submit an NDA for rusfertide in the fourth quarter of 2025.
• Initiate a PN-881 Phase 1 study in the fourth quarter of 2025.
• Nominate a development candidate for an oral hepcidin mimetic or ferroportin inhibitor in the fourth quarter of 2025.
• Nominate a development candidate for an oral peptide-based anti-obesity program by the end of the second quarter of 2025.
• JNJ to prepare comprehensive results from the ANTHEM-UC trial for presentation at upcoming medical congresses.
• Presentation of VERIFY trial results at the American Society of Clinical Oncology Annual Meeting in June 2025.

Key Dates

Keywords

rusfertide, icotrokinra, Takeda, JNJ, clinical trials, collaboration, revenue, Phase 3, NDA, VERIFY, PN-881, pharmaceuticals, biotech